The State Street SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the "Index"). Seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comprises the following sub-industries: BiotechnologySeeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocks. Allows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing
State Street SPDR S&P Biotech ETF · Issued by SPDR
| MRNA | Moderna Inc | 2.81% |
| TWST | Twist Bioscience Corp | 1.89% |
| APGE | Apogee Therapeutics Inc | 1.50% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.40% |
| HALO | Halozyme Therapeutics Inc | 1.39% |
| NTRA | Natera Inc | 1.37% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.34% |
| ORKA | Oruka Therapeutics Inc | 1.33% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.31% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.30% |

The Boring Company is reportedly raising $4 billion at a $20 billion valuation -- nearly four times its 2022 price tag -- as its Vegas Loop prepares to expand to the airport. Neuralink's brain-computer interface is now implanted in 21 patients, and the company is targeting $1 billion in annual revenue by 2031, pending FDA approval.